World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation

Alkomiet Hasan; Peter Falkai; Thomas Wobrock; Jeffrey Lieberman; Birte Glenthøj; Wagner F Gattaz; Florence Thibaut; Hans-Jürgen Möller; WFSBP Task Force on Treatment Guidelines for Schizophrenia

doi:10.3109/15622975.2015.1009163

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation

Alkomiet Hasan, Peter Falkai, Thomas Wobrock, Jeffrey Lieberman, Birte Glenthøj, Wagner F Gattaz, Florence Thibaut, Hans-Jürgen Möller, WFSBP Task Force on Treatment Guidelines for Schizophrenia

Department of Clinical Medicine

66 Citations (Scopus)

Abstract

These updated guidelines are based on the first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in the years 2005 and 2006. For this 2015 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations which are clinically and scientifically relevant. They are intended to be used by all physicians diagnosing and treating patients with schizophrenia. Based on the first version of these guidelines a systematic review, as well as a data extraction from national guidelines have been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and subsequently categorised into six levels of evidence (A-F) and five levels of recommendation (1-5). This third part of the updated guidelines covers the management of the following specific treatment circumstances: comorbid depression, suicidality, various comorbid substance use disorders (legal and illegal drugs), and pregnancy and lactation. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of patients with schizophrenia.

Original language	English
Journal	World Journal of Biological Psychiatry
Volume	16
Issue number	3
Pages (from-to)	142-70
Number of pages	29
ISSN	1562-2975
DOIs	https://doi.org/10.3109/15622975.2015.1009163
Publication status	Published - 1 Apr 2015

Keywords

Antidepressive Agents
Antipsychotic Agents
Biological Psychiatry
Breast Feeding
Depression
Disease Management
Drug Therapy, Combination
Electroconvulsive Therapy
Evidence-Based Medicine
Female
Humans
International Cooperation
Lactation
Pregnancy
Pregnancy Complications
Psychotherapy
Schizophrenia
Smoking Cessation
Substance-Related Disorders
Suicide
Transcranial Magnetic Stimulation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/15622975.2015.1009163

Fingerprint

Dive into the research topics of 'World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation'. Together they form a unique fingerprint.

Cite this

Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthøj, B., Gattaz, W. F., Thibaut, F., Möller, H-J., & WFSBP Task Force on Treatment Guidelines for Schizophrenia (2015). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World Journal of Biological Psychiatry, 16(3), 142-70. https://doi.org/10.3109/15622975.2015.1009163

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3 : Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. / Hasan, Alkomiet; Falkai, Peter; Wobrock, Thomas et al.

In: World Journal of Biological Psychiatry, Vol. 16, No. 3, 01.04.2015, p. 142-70.

Research output: Contribution to journal › Journal article › Research › peer-review

Hasan, A, Falkai, P, Wobrock, T, Lieberman, J, Glenthøj, B, Gattaz, WF, Thibaut, F, Möller, H-J & WFSBP Task Force on Treatment Guidelines for Schizophrenia 2015, 'World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation', World Journal of Biological Psychiatry, vol. 16, no. 3, pp. 142-70. https://doi.org/10.3109/15622975.2015.1009163

Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World Journal of Biological Psychiatry. 2015 Apr 1;16(3):142-70. doi: 10.3109/15622975.2015.1009163

Hasan, Alkomiet ; Falkai, Peter ; Wobrock, Thomas et al. / World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3 : Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. In: World Journal of Biological Psychiatry. 2015 ; Vol. 16, No. 3. pp. 142-70.

@article{8ff3335c74614dc184c3e44d5a3f469a,

title = "World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation",

abstract = "These updated guidelines are based on the first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in the years 2005 and 2006. For this 2015 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations which are clinically and scientifically relevant. They are intended to be used by all physicians diagnosing and treating patients with schizophrenia. Based on the first version of these guidelines a systematic review, as well as a data extraction from national guidelines have been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and subsequently categorised into six levels of evidence (A-F) and five levels of recommendation (1-5). This third part of the updated guidelines covers the management of the following specific treatment circumstances: comorbid depression, suicidality, various comorbid substance use disorders (legal and illegal drugs), and pregnancy and lactation. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of patients with schizophrenia.",

keywords = "Antidepressive Agents, Antipsychotic Agents, Biological Psychiatry, Breast Feeding, Depression, Disease Management, Drug Therapy, Combination, Electroconvulsive Therapy, Evidence-Based Medicine, Female, Humans, International Cooperation, Lactation, Pregnancy, Pregnancy Complications, Psychotherapy, Schizophrenia, Smoking Cessation, Substance-Related Disorders, Suicide, Transcranial Magnetic Stimulation",

author = "Alkomiet Hasan and Peter Falkai and Thomas Wobrock and Jeffrey Lieberman and Birte Glenth{\o}j and Gattaz, {Wagner F} and Florence Thibaut and Hans-J{\"u}rgen M{\"o}ller and {WFSBP Task Force on Treatment Guidelines for Schizophrenia}",

year = "2015",

month = apr,

day = "1",

doi = "10.3109/15622975.2015.1009163",

language = "English",

volume = "16",

pages = "142--70",

journal = "World Journal of Biological Psychiatry",

issn = "1562-2975",

publisher = "Taylor & Francis",

number = "3",

}

TY - JOUR

T1 - World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3

T2 - Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation

AU - Hasan, Alkomiet

AU - Falkai, Peter

AU - Wobrock, Thomas

AU - Lieberman, Jeffrey

AU - Glenthøj, Birte

AU - Gattaz, Wagner F

AU - Thibaut, Florence

AU - Möller, Hans-Jürgen

AU - WFSBP Task Force on Treatment Guidelines for Schizophrenia

PY - 2015/4/1

Y1 - 2015/4/1

N2 - These updated guidelines are based on the first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in the years 2005 and 2006. For this 2015 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations which are clinically and scientifically relevant. They are intended to be used by all physicians diagnosing and treating patients with schizophrenia. Based on the first version of these guidelines a systematic review, as well as a data extraction from national guidelines have been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and subsequently categorised into six levels of evidence (A-F) and five levels of recommendation (1-5). This third part of the updated guidelines covers the management of the following specific treatment circumstances: comorbid depression, suicidality, various comorbid substance use disorders (legal and illegal drugs), and pregnancy and lactation. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of patients with schizophrenia.

AB - These updated guidelines are based on the first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in the years 2005 and 2006. For this 2015 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations which are clinically and scientifically relevant. They are intended to be used by all physicians diagnosing and treating patients with schizophrenia. Based on the first version of these guidelines a systematic review, as well as a data extraction from national guidelines have been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and subsequently categorised into six levels of evidence (A-F) and five levels of recommendation (1-5). This third part of the updated guidelines covers the management of the following specific treatment circumstances: comorbid depression, suicidality, various comorbid substance use disorders (legal and illegal drugs), and pregnancy and lactation. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of patients with schizophrenia.

KW - Antidepressive Agents

KW - Antipsychotic Agents

KW - Biological Psychiatry

KW - Breast Feeding

KW - Depression

KW - Disease Management

KW - Drug Therapy, Combination

KW - Electroconvulsive Therapy

KW - Evidence-Based Medicine

KW - Female

KW - Humans

KW - International Cooperation

KW - Lactation

KW - Pregnancy

KW - Pregnancy Complications

KW - Psychotherapy

KW - Schizophrenia

KW - Smoking Cessation

KW - Substance-Related Disorders

KW - Suicide

KW - Transcranial Magnetic Stimulation

U2 - 10.3109/15622975.2015.1009163

DO - 10.3109/15622975.2015.1009163

M3 - Journal article

C2 - 25822804

SN - 1562-2975

VL - 16

SP - 142

EP - 170

JO - World Journal of Biological Psychiatry

JF - World Journal of Biological Psychiatry

IS - 3

ER -